PracticeVideosBlogFlashcardsEspañol
All Practice Exams

100+ Free Facharzt FMH Urologie Practice Questions

Prepare for the Facharzt FMH für Urologie / Spécialiste FMH en urologie exam with instant access — no signup required.

✓ No registration✓ No credit card✓ No hidden fees✓ Start practicing immediately
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Swiss FMH Medical Specialist Examinations (Facharzt SIWF/FMH)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Facharzt FMH Allgemeine Innere Medizin (Switzerland)

Practice Questions

Facharzt FMH Anästhesiologie (Switzerland)

Practice Questions

Facharzt FMH Chirurgie (Switzerland)

Practice Questions

Facharzt FMH Dermatologie und Venerologie (Switzerland)

Practice Questions

Facharzt FMH Gynäkologie und Geburtshilfe (Switzerland)

Practice Questions

Facharzt FMH Hals-Nasen-Ohren (Otorhinolaryngologie) (Switzerland)

Practice Questions
2026 Statistics

Key Facts: Facharzt FMH Urologie Exam

EBU + SGU

Exam Format

SIWF / SGU Examination Regulations

100–110

Written EBU MCQs

European Board of Urology

6 Years

Postgraduate Training

SIWF Weiterbildungsprogramm

120 min

Written Exam Duration

EBU Examination Standard

Lifetime

FMH Title Validity

Swiss Medical Association (FMH)

100

Practice Questions

OpenExamPrep

The Facharzt FMH Urologie credential certifies specialist urologists in Switzerland through SIWF and SGU (SWISS UROLOGY). Qualification requires passing the European Board of Urology (EBU) written examination (100–110 MCQs in English) and the SGU oral-practical board examination, covering uro-oncology, endourology, BPH, functional urology, andrology, and emergencies.

Sample Facharzt FMH Urologie Practice Questions

Try these sample questions to test your Facharzt FMH Urologie exam readiness. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 64-year-old man with a baseline PSA of 6.2 ng/mL and a normal digital rectal examination undergoes multiparametric MRI (mpMRI) of the prostate. The MRI reveals a 14 mm focal lesion in the peripheral zone of the right mid-gland with marked hypointensity on ADC, marked hyperintensity on high b-value DWI, and early focal contrast enhancement, classified as PI-RADS 4. According to EAU and Swiss guidelines, what is the most appropriate next step in diagnostic management?
A.Combined MRI-targeted biopsy (cognitive, fusion, or in-bore) plus systematic template core biopsies of the prostate
B.Systematic 12-core transrectal ultrasound-guided biopsy alone, omitting targeted cores as PI-RADS 4 has low positive predictive value
C.Repeat multiparametric MRI in 6 months to assess for lesion growth before deciding on tissue biopsy
D.Immediate radical prostatectomy without prior histological confirmation given the definitive MRI appearance
Explanation: According to EAU Guidelines on Prostate Cancer, when mpMRI is positive (PI-RADS 3–5) in biopsy-naïve patients, a combined approach combining targeted biopsy of the index lesion with systematic biopsy is recommended. Combining targeted and systematic cores significantly increases the detection rate of clinically significant prostate cancer (ISUP Grade Group ≥ 2) while reducing the misclassification of multifocal disease.
2A 58-year-old asymptomatic man is diagnosed with prostate adenocarcinoma following a combined MRI-targeted and systematic biopsy. Pathology confirms ISUP Grade Group 1 (Gleason score 3+3=6) in 2 out of 14 cores, with a maximum core involvement of 30%. His PSA is 4.8 ng/mL, prostate volume is 45 mL (PSA density 0.11 ng/mL/cc), and digital rectal examination is normal (cT1c). According to EAU guidelines, what is the preferred initial management strategy?
A.Immediate robotic-assisted laparoscopic radical prostatectomy with bilateral pelvic lymphadenectomy
B.Active surveillance with scheduled PSA monitoring, repeat mpMRI, and confirmatory/surveillance biopsies
C.External beam radiation therapy with 18 months of androgen deprivation therapy
D.High-intensity focused ultrasound (HIFU) hemiablation of the prostate gland
Explanation: Active surveillance is the preferred standard of care for men with low-risk localized prostate cancer (ISUP Grade Group 1, PSA < 10 ng/mL, cT1c–cT2a, PSA density < 0.15 ng/mL/cc, and low tumor volume). Landmark trials (e.g., ProtecT) demonstrate equivalent 10- and 15-year prostate cancer-specific survival compared with immediate radical treatment, while avoiding treatment-related urinary and sexual toxicities.
3A 66-year-old man with newly diagnosed high-risk localized prostate cancer (cT3a on MRI, PSA 24 ng/mL, biopsy ISUP Grade Group 4 [Gleason 4+4=8]) is scheduled for robotic-assisted radical prostatectomy. A validated nomogram calculates a 28% risk of pelvic lymph node involvement. According to EAU guidelines, what is the standard anatomical template for extended pelvic lymph node dissection (ePLND)?
A.Removal of obturator fossa lymph nodes exclusively
B.Removal of external iliac and superficial inguinal lymph nodes
C.Removal of obturator, external iliac, and internal iliac (hypogastric) lymph node packets bilaterally
D.Removal of common iliac, para-aortic, and paracaval lymph nodes up to the renal vessels only
Explanation: According to EAU guidelines, when the nomogram-predicted risk of nodal metastasis exceeds 5–7%, an extended pelvic lymph node dissection (ePLND) should be performed. The standardized anatomical template of ePLND includes the removal of nodes within the obturator fossa (along the obturator nerve), along the external iliac vessels (superiorly to the bifurcation), and along the internal iliac (hypogastric) vessels bilaterally. Dissection up to the common iliac bifurcation provides optimal staging accuracy.
4A 62-year-old man underwent radical prostatectomy for pT3a pN0 R1 prostate adenocarcinoma 18 months ago. His post-operative PSA nadir was < 0.01 ng/mL. On routine follow-up, his PSA is measured at 0.22 ng/mL and confirmed at 0.26 ng/mL 6 weeks later. PSMA-PET/CT shows no evidence of distant visceral or bone metastasis. What is the definition of this condition and the recommended initial management?
A.Castration-resistant progression; initiate enzalutamide monotherapy immediately
B.Benign anastomotic PSA leak; reassure the patient and repeat PSA in 12 months
C.Systemic failure; perform surgical resection of retroperitoneal lymph nodes
D.Biochemical recurrence post-prostatectomy; initiate early salvage radiotherapy to the prostatic bed
Explanation: Biochemical recurrence (BCR) following radical prostatectomy is defined by the EAU and AUA as two consecutive rising PSA values ≥ 0.20 ng/mL. Early salvage radiotherapy to the prostatic bed (often combined with short-course ADT for adverse features) offers the best oncological cure when initiated at low PSA levels (PSA < 0.5 ng/mL, ideally < 0.2–0.3 ng/mL).
5A 60-year-old man presents with bone pain. Workup reveals de novo metastatic hormone-sensitive prostate cancer (mHSPC) with extensive bone metastases (8 lesions across the spine and pelvis, including 4 outside the axial skeleton) and multiple pelvic lymph nodes (high-volume disease by CHAARTED criteria). His ECOG performance status is 0. Based on the PEACE-1 and ARASENS trials and current EAU guidelines, what is the preferred first-line systemic treatment?
A.Triplet therapy: Androgen deprivation therapy (ADT) plus docetaxel chemotherapy plus an androgen receptor pathway inhibitor (darolutamide or abiraterone)
B.ADT monotherapy with an LHRH agonist alone, reserving novel antiandrogens for castration resistance
C.Docetaxel monotherapy for 6 cycles without androgen deprivation therapy
D.Bicalutamide 50 mg daily monotherapy with palliative focal bone radiotherapy
Explanation: In fit patients presenting with de novo, high-volume metastatic hormone-sensitive prostate cancer (mHSPC), triplet therapy consisting of ADT + docetaxel (6 cycles) + an ARPI (darolutamide per ARASENS or abiraterone acetate per PEACE-1) significantly prolongs overall survival and time to castration resistance compared to ADT + docetaxel doublet therapy.
6A 74-year-old man with prostate cancer on continuous ADT (serum testosterone 18 ng/dL) develops a rapid PSA rise from 2.1 to 8.4 ng/mL over 5 months, resulting in a PSA doubling time (PSADT) of 4.2 months. Conventional imaging (contrast CT of chest/abdomen/pelvis and 99mTc bone scan) shows no evidence of distant metastatic disease. According to the PROSPER, SPARTAN, and ARAMIS trials, what is the standard management for this non-metastatic castration-resistant prostate cancer (nmCRPC)?
A.Immediate cessation of ADT to allow androgen receptor recovery
B.Continue ADT and add an androgen receptor pathway inhibitor (apalutamide, darolutamide, or enzalutamide)
C.Initiate systemic cytotoxic chemotherapy with cabazitaxel plus prednisone
D.Observation with serial PSA monitoring until macroscopic bone metastases appear on bone scintigraphy
Explanation: In non-metastatic castration-resistant prostate cancer (nmCRPC) with a high risk of progression (PSADT ≤ 10 months), landmark Phase III trials (ARAMIS, SPARTAN, PROSPER) demonstrated that adding an ARPI (darolutamide, apalutamide, or enzalutamide) to continued ADT significantly extends metastasis-free survival (MFS) and overall survival (OS) compared to ADT alone.
7A 69-year-old man with metastatic castration-resistant prostate cancer (mCRPC) experiences disease progression with new bone lesions following prior therapy with enzalutamide. Next-generation genomic sequencing of his tumor biopsy reveals a deleterious, loss-of-function BRCA2 mutation. Based on the PROfound Phase III trial, which targeted agent is specifically approved and recommended for this patient?
A.Erlotinib
B.Sunitinib
C.Olaparib
D.Alpelisib
Explanation: Olaparib is an oral poly(ADP-ribose) polymerase (PARP) inhibitor. In the Phase III PROfound trial, olaparib demonstrated significant improvements in radiographic progression-free survival (rPFS) and overall survival (OS) compared to an ARPI switch in men with mCRPC harboring BRCA1, BRCA2, or ATM mutations who had progressed on prior enzalutamide or abiraterone.
8A 71-year-old patient with progressive mCRPC who previously progressed on abiraterone acetate and docetaxel chemotherapy is being evaluated for Lutetium-177-PSMA-617 radioligand therapy. According to the VISION trial eligibility criteria and international consensus guidelines, which of the following imaging prerequisites must be met before initiating Lu-177-PSMA-617?
A.A negative 99mTc-bone scan with solitary pelvic nodal disease only
B.High FDG uptake on 18F-FDG PET with complete absence of PSMA expression on 68Ga-PSMA-PET
C.Serum PSA > 50 ng/mL with measurable liver metastases on non-contrast ultrasound
D.High PSMA expression on 68Ga-PSMA-11 (or 18F-PSMA-1007) PET/CT across all metastatic lesions, with no discordant PSMA-negative/FDG-positive lesions
Explanation: In the Phase III VISION and TheraP trials, eligibility for 177Lu-PSMA-617 radioligand therapy requires intense PSMA tracer uptake on diagnostic PSMA-PET (uptake significantly greater than normal liver parenchyma in all dominant lesions). The presence of discordant PSMA-negative, metabolically active (FDG-positive) lesions indicates PSMA-negative clonal disease that will not respond to radioligand therapy.
9A 70-year-old man completed definitive external beam radiation therapy (78 Gy) plus 6 months of ADT for intermediate-risk prostate cancer 3 years ago. His lowest recorded PSA (nadir) was 0.4 ng/mL at 18 months post-RT. Over the past 9 months, serial PSA measurements are 1.2, 1.8, and 2.5 ng/mL. According to the ASTRO-Phoenix consensus criteria, does this patient meet the definition of biochemical failure?
A.Yes, because his PSA has risen by ≥ 2.0 ng/mL above his post-radiation PSA nadir (0.4 + 2.0 = 2.4 ng/mL)
B.No, because biochemical failure post-radiotherapy requires a single PSA value > 10.0 ng/mL
C.No, because biochemical failure post-radiotherapy is defined as any PSA rise above 0.2 ng/mL, which occurred at 1.2 ng/mL
D.Yes, but only if histological recurrence is confirmed by transrectal prostate biopsy
Explanation: The ASTRO-Phoenix consensus definition for biochemical recurrence following definitive external beam radiation therapy (with or without ADT) is a PSA rise of ≥ 2.0 ng/mL above the post-treatment PSA nadir (nadir + 2.0 ng/mL). Here, nadir (0.4) + 2.0 = 2.4 ng/mL; the current level of 2.5 ng/mL confirms biochemical recurrence.
10During nerve-sparing radical prostatectomy, precise preservation of the neurovascular bundles (NVB) responsible for erectile function requires understanding their fascial anatomy. Where do the cavernous nerves primarily course relative to the prostatic capsule and adjacent fascial layers?
A.Anterior to the puboprostatic ligaments within the space of Retzius
B.Posterolateral to the prostate, between the prostatic fascia and the lateral pelvic fascia (levator fascia)
C.Directly within the lumen of the seminal vesicles
D.Medial to the prostatic urethra within the transition zone
Explanation: The cavernous nerve fibers travel in the posterolateral neurovascular bundle (NVB), embedded in adipose and connective tissue located between the prostatic fascia (inner layer) and the lateral pelvic / levator fascia (outer layer), adjacent to Denonvilliers' fascia posteriorly. An intrafascial or interfascial dissection plane allows preservation of these delicate autonomic fibers.

About the Facharzt FMH Urologie Exam

The Facharzt FMH für Urologie (Specialist in Urology FMH) is the Swiss Federal specialist medical title granting full independent practice rights in urology and urological surgery throughout Switzerland. Governed by the SIWF (Swiss Institute for Postgraduate and Continuous Medical Training) and the SGU (Swiss Society of Urology / SWISS UROLOGY), board certification requires completion of a structured 6-year postgraduate curriculum, passing the Swiss Basic Surgical Exam (Basisexamen Chirurgie), fulfilling the certified surgical logbook (Operationskatalog), and passing both parts of the official specialist examination. The theoretical-written component is the European Board of Urology (EBU) Examination, followed by the SGU oral-practical board examination. The syllabus encompasses uro-oncology (prostate, bladder, renal, testicular, and penile cancers), endourology and urolithiasis, benign prostatic hyperplasia (BPH / LUTS), functional and neuro-urology, urinary incontinence, andrology and sexual medicine, male infertility, pediatric urology, and urological emergencies. Note on format and language: The official written EBU examination is administered in English, while the SGU oral examination is conducted in Swiss national languages (German or French) or English. This question bank is an English-language multiple-choice study adaptation created by OpenExamPrep—not an official EBU/SGU examination release—specifically designed to train high-yield diagnostic reasoning, surgical indications, and guideline-based therapeutic decision-making.

Assessment

Two-part qualifying examination: 1) The written European Board of Urology (EBU) online examination consisting of 100–110 single-best-answer MCQs in English, and 2) The SGU oral-practical board examination organized by the SGU examination committee (Prüfungskommission) evaluating real-world clinical vignettes, intraoperative decision-making, and emergency scenarios.

Time Limit

120 minutes written examination (EBU Online Examination) plus approximately 60–90 minutes structured oral-practical examination

Passing Score

Criterion-referenced standard passing score on the written EBU examination (typically ~60–65% raw score) and a structured passing evaluation across all clinical case stations assessed by the SGU examination committee

Exam Fee

EBU Written Examination fee ~EUR 450–650; SGU Oral Examination fee CHF 1,500; SIWF FMH Title Application fee CHF 1,000–2,500 (Schweizerisches Institut für ärztliche Weiter- und Fortbildung (SIWF / FMH) and Schweizerische Gesellschaft für Urologie (SGU / SWISS UROLOGY), utilizing the European Board of Urology (EBU) Examination)

Facharzt FMH Urologie Exam Content Outline

38%

Uro-Oncology: Prostate, Bladder, Kidney, Testis & Penis

Risk stratification, multiparametric MRI (PI-RADS), prostate cancer active surveillance, radical prostatectomy, systemic therapy (ARPIs, ADT, lutetium-177-PSMA-617), NMIBC/MIBC staging and intravesical BCG/radical cystectomy, UTUC management, renal cell carcinoma histology, partial/radical nephrectomy, targeted/immunotherapy, testicular germ cell tumor staging/orchiectomy/RPLND, and penile squamous cell carcinoma.

20%

Endourology, Lithiasis & Urinary Tract Infections

Etiology, metabolic evaluation, and stone composition analysis (calcium oxalate, uric acid, cystine, struvite/infection stones); surgical modalities including ESWL, flexible ureterorenoscopy (URS/RIRS), miniaturized and standard PCNL; chemolitholysis; double-J stenting; complicated UTI, acute obstructive pyelonephritis, and sepsis protocols.

15%

Benign Prostatic Hyperplasia (BPH / LUTS) & Lower Urinary Tract Obstruction

Clinical assessment (IPSS, uroflowmetry, post-void residual, pressure-flow urodynamics), pharmacotherapy (alpha-1 blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, antimuscarinics, beta-3 agonists), and minimally invasive / endoscopic / robotic surgical interventions (monopolar/bipolar TURP, HoLEP, ThuLEP, laser enucleation, Rezum, Aquablation, simple prostatectomy).

15%

Functional Urology, Neuro-Urology, Incontinence & Reconstruction

Overactive bladder (OAB), stress urinary incontinence (SUI), mid-urethral slings, artificial urinary sphincter (AUS), neurogenic lower urinary tract dysfunction (NLUTD: spinal cord injury, multiple sclerosis, spina bifida), videourodynamics, botulinum toxin A, sacral neuromodulation, urethral stricture repair (urethroplasty, buccal mucosa graft), and urinary diversion.

12%

Andrology, Male Infertility, Pediatric Urology & Urological Emergencies

Erectile dysfunction (ED), Peyronie's disease, hypogonadism, priapism (ischemic vs non-ischemic), male factor infertility (semen analysis, azoospermia, varicocelectomy), pediatric conditions (vesicoureteral reflux, cryptorchidism/orchidopexy, hypospadias, PUV), acute scrotal pathology (testicular torsion vs epididymitis), Fournier gangrene, and genitourinary trauma.

How to Pass the Facharzt FMH Urologie Exam

What You Need to Know

  • Passing score: Criterion-referenced standard passing score on the written EBU examination (typically ~60–65% raw score) and a structured passing evaluation across all clinical case stations assessed by the SGU examination committee
  • Assessment: Two-part qualifying examination: 1) The written European Board of Urology (EBU) online examination consisting of 100–110 single-best-answer MCQs in English, and 2) The SGU oral-practical board examination organized by the SGU examination committee (Prüfungskommission) evaluating real-world clinical vignettes, intraoperative decision-making, and emergency scenarios.
  • Time limit: 120 minutes written examination (EBU Online Examination) plus approximately 60–90 minutes structured oral-practical examination
  • Exam fee: EBU Written Examination fee ~EUR 450–650; SGU Oral Examination fee CHF 1,500; SIWF FMH Title Application fee CHF 1,000–2,500

Keys to Passing

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Facharzt FMH Urologie Study Tips from Top Performers

1Master EAU Uro-Oncology Treatment Algorithms: Be completely fluent in risk stratification for localized prostate cancer (low, intermediate, high), active surveillance criteria (PRIAS/EAU), indications for radical prostatectomy vs radiotherapy + ADT, doublet/triplet systemic therapy in metastatic hormone-sensitive prostate cancer (mHSPC: ADT + ARPI +/- docetaxel), and intravesical BCG induction and maintenance protocols for high-risk NMIBC.
2Understand Endourological Energy Modalities & Settings: Know the physics, laser settings (high frequency/low pulse energy for dusting vs low frequency/high energy for fragmentation with Holmium:YAG or Thulium Fiber Laser / TFL), irrigation pressure management, and indications for flexible URS vs mini-PCNL vs standard PCNL for renal calculi >2 cm or lower pole stones with unfavorable anatomy.
3Memorize Urodynamic Tracing Interpretations & Neuro-Urology Classifications: Be proficient in recognizing detrusor overactivity, detrusor sphincter dyssynergia (DSD), detrusor underactivity, intrinsic sphincter deficiency (ISD), and bladder compliance calculations, especially in patients with spinal cord injury (autonomic dysreflexia protocols) and multiple sclerosis.
4Review Reconstructive Urology & Stricture Guidelines: Know the indications and operative principles for anterior vs posterior urethral strictures, including end-to-end anastomotic urethroplasty for short bulbar strictures (<2 cm) and ventral/dorsal onlay buccal mucosa graft urethroplasty for longer strictures or penile urethral strictures (avoiding repeated endoscopic urethrotomies).
5Differentiate Acute Scrotal Pathologies & Priapism Types: Memorize the key clinical, ultrasound, and blood gas differences between low-flow (ischemic: dark, hypoxic, acidotic blood, painful, requires immediate aspiration and phenylephrine) and high-flow (non-ischemic: bright red, well-oxygenated blood, painless, post-traumatic AV fistula, managed conservatively or with selective embolization) priapism.

Frequently Asked Questions

What is the Facharzt FMH für Urologie title?

The Facharzt FMH für Urologie is the federally recognized specialist medical title awarded by the SIWF / FMH (Swiss Medical Association) upon completion of at least 6 years of accredited postgraduate residency in urology and surgical fundamentals, passing the Swiss Basic Surgical Exam (Basisexamen Chirurgie), passing the European Board of Urology (EBU) written examination and the SGU oral-practical board examination, and fulfilling the official SIWF surgical operation catalog.

How is the Swiss Urology specialist examination structured?

The specialist examination consists of two mandatory parts: 1) The written European Board of Urology (EBU) Examination, consisting of 100–110 single-best-answer MCQs administered online in English, and 2) The SGU oral-practical board examination, which evaluates clinical diagnostic reasoning, radiological interpretation, surgical technique indications, and emergency management before a panel of Swiss urology experts.

How do Swiss candidates register for the EBU written examination?

Candidates undergoing urology residency in Switzerland must register for the EBU examination exclusively through the Swiss Society of Urology (SGU / SWISS UROLOGY) website (www.swissurology.ch). Direct registrations through the EBU website are not accepted for Swiss certification.

What clinical guidelines form the primary foundation of the examination?

The written EBU examination and SGU oral board are primarily based on the European Association of Urology (EAU) Guidelines, SIWF curriculum requirements, and consensus recommendations from the Swiss Society of Urology (SGU).

Why is this practice bank presented in English?

The official written European Board of Urology (EBU) Examination is written and administered entirely in English across all participating European countries, including Switzerland. Furthermore, major urological reference literature, EAU Guidelines, and clinical trials are published in English. This practice bank adapts Swiss and EBU blueprint standards into 100 high-yield English-language questions.

What are the most critical urological emergencies tested on the board?

High-yield emergencies include acute testicular torsion (urgent surgical exploration within 6 hours), infected obstructive urolithiasis / septic stone (immediate urinary decompression via double-J stent or percutaneous nephrostomy), ischemic priapism (intracavernosal phenylephrine and aspiration/shunt), Fournier gangrene (emergent surgical debridement and broad-spectrum antibiotics), and traumatic genitourinary injuries (renal lacerations, bladder rupture, and posterior urethral disruption).